Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX:PBT) covers the month of June 2009, with a specific reporting date of June 16, 2009. The registrant is a foreign private issuer based in Australia. The filing serves as a notice under Section 708A(5) of the Corporations Act regarding the issuance of unlisted options without disclosure to investors under Part 6D.2.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to employee incentives.
- Ordinary Shares Quoted on ASX: 202,710,473
- New Securities Issued: Unlisted Options (Nil consideration)
- Issue Date: June 16, 2009
Material Changes and New Issuance Details
On June 16, 2009, the company issued two tranches of unlisted options under the 2004 ASX Plan. These securities were issued at nil consideration as part of Employee Incentive Schemes and Consulting Agreements.
| ASX Code | Number of Options | Exercise Price | Expiry Date | Purpose |
|---|---|---|---|---|
| PBTAF | 904,981 | Nil | October 31, 2010 | Employee Incentive Scheme & Consulting Agreements |
| PBTAB | 194,837 | Nil | August 7, 2014 | Employee Incentive Scheme |
The options will remain unlisted until exercised into ordinary shares. Upon exercise, the resulting shares will rank equally with existing quoted securities.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on operations, or discussion of risks and contingencies beyond the standard regulatory warranties. The company confirmed compliance with Chapter 2M and Section 674 of the Corporations Act as of the filing date. No unusual items or material changes to the business model were disclosed.
Investor Verification Checklist
- Verify the total number of outstanding options across all classes (including PBTAK, PBTAW, PBTAA, etc.) to assess potential dilution.
- Confirm the terms of the 2004 ASX Plan to understand vesting schedules and eligibility for the nil-cost options.
- Review the company's cash position in subsequent filings, as nil-cost option issuances do not generate immediate capital inflow.
- Check for any subsequent filings regarding the exercise of these specific option tranches (PBTAF and PBTAB).